Clinical psychopharmacology and other somatic therapies

The Medical Basis of Psychiatry: Third Edition

Volumn , Issue , 2008, Pages 577-634

  Perry, Paul J ^a,b   Wehring, Heidi J ^b   Alexander, Bruce ^a   Liskow, Barry ^c  

^a UNIVERSITY OF IOWA   (United States)

^b TOURO UNIVERSITY CALIFORNIA   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety disorders; Bipolar disorder; Dementias; Major depression; Psychopharmacology; Schizophrenia; Sleep medications

Indexed keywords

EID: 79951709348     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-252-6_34     Document Type: Chapter

References (522)

1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-564.
2. Love RC, Mackowick M, Carpenter D, et al. Expert consensus-based medication-use evaluation criteria for atypical antipsy-chotic drugs. Am J Health Syst Pharm 2003; 60:2455-2470.
3. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19:287-302.
4. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsy-chotics in the treatment of schizophrenia: systematic overview and meta-regression analysis [see comment]. BMJ 2000; 321:1371-1376.
5. Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000; 61:14-17.
6. Daniel DG, Kinon BJ, Litman RE, et al. Algorithms for the treatment of schizophrenia. Psychopharmacol Bull 1995; 31:461-467.
7. Leucht S, Pitschel-Walz D, Abraham D, et al. Efficacy and extrapyramidal side effects of the new antipsychotics olan-zapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 1999; 35:51-68.
8. Keefe RSE, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161(6):985-995.
9. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaf-fective disorder. Am J Psychiatry 1999; 156:544-549.
10. Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet 1995; 346:820-825.
11. Janicak PG. The relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. J Clin Psychiatry 1993; 54(Suppl 9): 35-41.
12. Alexander B. Antipsychotics: how strict the formulary? Drug Intell Clin Pharm 1988; 22:324-326.
13. Kissling W, Kane JM, Barnes TR, et al. Guidelines for neuroleptic relapse prevention in schizophrenia: Towards a consensus view. In: Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Kissling W, eds. Springer-Verlag 1991; 155-163.
14. Freedman R. Drug therapy: Schizophrenia. N Engl J Med 2003; 349:1738-1749.
15. Davis JM, Chen N, Glick ID. Web supplement: a meta-analysis of the efficacy of second-generation antipsycho-tics. www.psych.uic.edu/faculty/davis/ Meta analysis.pdf 2005; Access date 8/20/06.
16. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with schizophrenia. N Engl J Med 2005; 353:1209-1223
17. Anonymous: Clozaril [clozapine] product information; 1998.
18. Jayaram MB, Hosalli P: Risperidone versus olanzapine for schizophrenia. The Cochrane Database of Systematic Reviews 2005.
19. Meltzer HY, Okayli G. Reduction of suicidality during cloza-pine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183-190.
20. McEvoy GK, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163(4):600-610.
21. Lindstrom LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988; 77:524-529.
22. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Comm Psychiatry 1990; 41:882-885.
23. Miller DD, Perry PJ, Cadoret RJ, et al. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35:8-15.
24. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162:130-136.
25. Yagcloglu AEA, Akdede BBK, Turgut TI, et al. A double-blind controlled trial of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005; 66:63-72.
26. Banov MD, Zarate CA, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994; 55: 295-300.
27. Yatham LN. Atypical antipsychotics for bipolar disorder. Psychiatr Clin North Am 2005; 28:325-347.
28. Keck PE: The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. J Clin Psychiatry 2005; 66:5-11.
29. Perlis RH. The role of pharmacologic treatment guidelines for bipolar disorder. J Clin Psychiatry 2005; 66(Suppl 3):37-47.
30. Wragg RE, Jeste DV. Neuroleptics and alternative treatments: management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions. Psychiatr Clin North Am 1998; 11:195-213.
31. Schneider LS, Degerman KS. Psychosis of Alzheimer's disease: clinical characteristics and history. J Psychiatr Res 2004; 38:105-111.
32. Kane J, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Schizophrenia Res 2000; 41:39
33. Anonymous: Abilify [aripiprazole] product information; 2004.
34. Perry PJ, Miller DD. The clinical utility of clozapine plasma concentrations. In: Clinical Use of Neuroleptic Plasma Levels. Marder SR, Davis JM, Janicak PG, eds. American Psychiatric Association, Inc. 1993; pp 85-100
35. Anonymous: Clozaril [clozapine] product information. 2005
36. Anonymous: Zyprexa [olanzapine] product information. 2004.
37. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159:255-262.
38. Anonymous: Risperdal® [risperidone] product information. 2005
39. R [risperidone] product information. 2006
40. Anonymous: Seroquel [quetiapine] product information. 2005
41. Anonymous: Geodon [ziprasidone] product information. 2004.
42. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50:329-338.
43. Beasley CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124:159-167.
44. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death [see comment]. Am J Psychiatry 2001; 158:1774-1782.
45. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-123.
46. Herrmann N, Muhammad M, Lancet K. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161:1113-1115.
47. Gill SS, Rochon PA, Herrmann N, et al. SGA drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 26:445
48. Layton D, Harris S, Wilton, et al. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharm 2005; 19:473-482.
49. Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 2005; 17:1-13
50. Anonymous: Cymbalta [duloxetine] product information. 2004.
51. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334-1349.
52. Boehm G, Racoosin JA, Laughren TP, et al. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: Response to consensus statement. Diabetes Care 2004; 27:2088-2089.
53. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27(Suppl 1):S15-S35.
54. Kleinberg DL, Davis JM, DeCoster R et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopahrmacol 1999; 19:57-61.
55. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18:296-304.
56. Mendhekar DN, Lohia RC, Jiloha RC. Olanzapine-induced galactorrhea in a woman with psychotic illness. Aust NZ J Psychiatry 2004; 38:266.
57. Umbricht DSG, Pollack S, Kane JM, et al. Clozapine and weight gain. J Clin Psychiatry 1994; 55:157-160.
58. Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 2005; 25:250-254.
59. Alvir JMA, Lieberman JA. A reevaluation of the clinical characteristics of clozapine-induced granulocytosis in light of the United States experience. J Clin Psychiatry 1994; 55:87-89.
60. Alvir JMA, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994; 55:137-138.
61. Brown CS, Markowitz JS, Moore TR, et al. Atypical antipsy-chotics, part II: adverse drug reactions, drug interactions, and costs. Ann Pharmacotherapy 1999; 33:210-217.
62. Worrel JA, Marken PA, Beckman SE, et al. Atypical antipsy-chotic agents: a critical review. Am J Health Syst Pharm 2000; 57:238-255.
63. Koller EA, Cross JT, Doraiswamy PM, et al. Pancreatitis associated with atypical antipsychotics: from the food and drug administration's MedWatch surveillance system and published reports. Pharmacotherapy 2003; 23(9):1123-1130.
64. Cohen LJ. Risperidone. Pharmacotherapy 1994; 14:253-265.
65. Perry PJ, Alexander B, Liskow BI. Psychotropic Drug Handbook, 8th ed. Baltimore: Lippincott, Williams and Wilkins, 2006.
66. Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 2005; 65:1113-1138.
67. Tollefson GD, Beasley CM Jr, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154:1248-1254
68. Anonymous: Abilify [aripiprazole] product information. 2005.
69. Safferman A, Lieberman JA, Kane JM, et al. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17:247-261.
70. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409-1416.
71. Davis JM, Casper R. Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 1977; 14:260-282.
72. Davis JM, Janicak PG, Singla A, et al. Maintenance antipsy-chotic medication. In: Antipsychotic Drugs and Their Side Effects. Barnes TR, eds. Academic Press 1993; 182-203.
73. Wolkowitz OM. Rational polypharmacy in schizophrenia. Ann Clin Psychiatry 1993; 5:79-90.
74. Cheine M, Ahonen J, Wahlbeck K. Beta-blocker supplementation of standard drug treatment for schizophrenia [update of Cochrane Database Syst Rev. 2000;(3):CD000234; PMID: 10908467]. Cochrane Database of Systematic Reviews 2001; CD000234.
75. Leucht S, McGrath J, White P, et al. Carbamazepine for schizophrenia and schizoaffective psychoses [update of Cochrane Database Syst Rev. 2000;(2):CD001258; PMID: 10796431]. Cochrane Database of Systematic Reviews 2002; CD001258.
76. Tempier RP, Pawliuk NH. Conventional, atypical, and combination antipsychotic prescriptions: a 2-year comparison. J Clin Psychiatry 2003; 64:673-679
77. Stahl SM Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry 2002; 63(2):93-94.
78. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004; 161:700-706.
79. Keck PE Jr, McElroy SL, Strakowski SM. New developments in the pharmacologic treatment of schizoaffective disorder. J Clin Psychiatry 1996; 57:41-48.
80. Goodwin FK, Zis AP. Lithium in the treatment of mania, comparison with neuroleptics. Arch Gen Psychiatry 1979; 36:840-844.
81. Chou JC-Y. Recent advances in treatment of mania. J Clin Psychopharmacol 1991; 11:3-21.
82. Sernyak MJ, Woods SW. Chronic neuroleptic use in manic-depressive illness. Psychopharmacol Bull 1993; 29:375-381.
83. Keck PE, McElroy SL, Strakowski SM, et al. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J Clin Psychiatry 1996; 57:147-151.
84. Schneider LS, Pollock VE, Lyeness SA. A meta-analysis of controlled trials of neuroleptics. J Am Geriatr Soc 1990; 38:553-563.
85. Sunderland T. Treatment of the elderly suffering from psychosis and dementia. J Clin Psychiatry 1996; 57:53-56.
86. Black JL, Richelson E, Richardson JW. Antipsychotic agents: a clinical update. Mayo Clin Proc 1985; 60:777-789.
87. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45:79-91.
88. Waraich PS, Adams CE, Roque M, et al. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews 1992; CD001951.
89. Battaglia J. Pharmacological management of acute agitation. Drugs 2005; 65:1207-1222.
90. Ortiz A, Gershon S. The future of neuroleptic psychopharma-cology. J Clin Psychiatry 1986; 47(Suppl):3-11.
91. Aubree JC, Lader MH. High and very high dosage anti-psychotics: a critical review. J Clin Psychiatry 1980; 41: 341-350.
92. Brotman AW, McCormick S. A role for high-dose antipsy-chotics. J Clin Psychiatry 1990; 51:164-166.
93. Davis JM, Kane JM, Marder SR, et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry 1993; 54:24-30.
94. Marder SR, Ames D, Wirshing WC, et al. Schizophrenia. Psychiatr Clin North Am 1993; 16:567-587.
95. Marder SR, Wirshing WC, Van Putten T, et al. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia. Arch Gen Psychiatry 1994; 51:280-287.
96. Shenoy RS, Sadler AG, Goldberg SC, et al. Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. J Clin Psychopharmacol 1981; 1:141-145.
97. Groves JE, Mandel MR. The long-acting phenothiazines. Arch Gen Psychiatry 1975; 32:893-900.
98. Yadalam KG, Simpson GM. Changing from oral to depot fluphenazine. J Clin Psychiatry 1988; 49:346-348.
99. Johnson DAW. Antipsychotic medication: clinical guidelines for maintenance therapy. J Clin Psychiatry 1985; 46(Suppl): 6-15.
100. Chouinard G, Annable L, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. J Clin Psychopharmacol 1989; 9:247-253.
101. Kane JM. Dosage strategies with long-acting injectable neuroleptics including haloperidol decanoate. J Clin Psychopharmacol 1986; 6(Suppl):20-23.
102. Beresford R, Ward A. Haloperidol decanoate: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 1987; 33:31-49.
103. De Cuyper H, Bollen J, van Praag HM, et al. Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration. Br J Psychiatry 1986; 148:560-566.
104. Gitlin MJ, Midha KK, Fogeson D, et al. Persistence of fluphenazine in plasma after decanoate withdrawal. J Clin Psychopharmacol 1988; 8:53-56.
105. Nayak RK, Doose DR, Nair NPV. The bioavailability and phar-macokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol 1987; 27:144-150.
106. Wistedt B, Wiles DH, Kolakowska T. Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics (letter). Lancet 1981; 1163.
107. Kissling W, Moller HJ, Walter K, et al. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side effects, dosage and serum levels during a six month treatment for relapse prevention. Pharmacopsychiatry 1985; 18:240-245.
108. Raskind MA, Risse SE. Antipsychotic drugs and the elderly. J Clin Psychiatry 1986; 47(Suppl):17-22.
109. Whalley LJ. Drug treatment of dementia. Br J Psychiatry 1989; 155:595-611.
110. Rhoades HM, Overall JE. Side effect potentials of different antipsychotic and antidepressant drugs. Psychopharmacol Bull 1984; 20:83-88.
111. Malhotra AK, Litman RE, Pickar D. Adverse effects of antipsy-chotic drugs. Drug Saf 1993; 9(6):429-436.
112. Simpson GM, Pi EH, Sramek JJ. ADR of antipsychotic agents. Drugs 1981; 21:138-151.
113. Shader RI, DiMascio A, eds. Psychotropic drug side effects, clinical and theoretical perspectives. Baltimore: Williams and Wilkins, 1970; 4-9, 63-85, 92-106, 116-123, 149-174, 175-198
114. Anonymous: Mellaril [thioridazine] product information. 2000.
115. Hartigan-Go K, Bateman DN, Nyberg G, et al. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996; 60: 543-553.
116. Opler LA, Feinberg SS. The role of pimozide in clinical psychiatry: a review. J Clin Psychiatry 1991; 52(5):221-233.
117. Tueth MJ, Cheong JA. Clinical uses of pimozide. South Med J 1993; 48(3):344-349.
118. Sultana A, McMonagle T. Pimozide for schizophrenia or related psychoses [update of Cochrane Database Syst Rev. 2000;(2):CD001949; PMID: 10796672]. Cochrane Database of Systematic Reviews 2000; CD001949.
119. Sullivan G, Lukoff D. Sexual side effects of antipsychotic medication: evaluation and interventions. Hospital and Community Psychiatry 1990; 41:1238-1241.
120. Zito J, Sofair JB, Jaeger J. Self-reported neuroendocrine effects of antipsychotics in women: a pilot study. DICP Ann Pharma-cother 1990; 24:176-180.
121. Inoue H, Hazama H, Ogura C, et al. Neuroendocrinological study of amenorrhea induced by antipsychotic drugs (letter). Folia Psychiatr Neurol (Jpn) 1980; 34:181.
122. Overall JE. Prior psychiatric treatment and the development of breast cancer. Arch Gen Psychiatry 1978; 35:898-899.
123. Brookes G, Ahmed AG. Pharmacological treatments for psychosis-related polydipsia. The Cochrane Database of Systematic Reviews, 2002.
124. Leadbetter RA, Shutty MS. Differential effects of neuroleptics and clozapine on polydipsia and intermittent hyponatremia. J Clin Psychiatry 1994; 55:110-113.
125. Parent MM, Roy S, Sramek J, et al. Effect of molindone on weight change in hospitalized schizophrenic patients. Drug Intell Clin Pharm 1986; 20:873-875.
126. Caroff SN, Mann SC, Campbell EC. Neuroleptic malignant syndrome. Adverse Drug Reaction Bulletin 2001; 209: 799-802.
127. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77:185-202.
128. Rosenberg MR, Green M. Neuroleptic malignant syndrome. Arch Intern Med 1989; 149:1927-1931.
129. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989; 50:18-25.
130. Goldberg PE, Weinberger DR. Effect of neuroleptic medication on cognition of patients with schizophrenia: a review of recent studies. J Clin Psychiatry 1996; 57 (Suppl 9):62-65.
131. Lee A. Treatment of drug-induced dystonic reactions. JACED 1979; 8:453-457.
132. Van Putten T, May PRA, Marder SA. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984; 41: 1036-1039.
133. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychophar-macol 1990; 10:12-21.
134. Wirshing WC, Freidenberg DL, Cummings JL, et al. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism. J Clin Psychophar-macol 1989; 9:407-411.
135. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989; 50:322-328.
136. Casey DE, Povlsen UJ, Meidahl B, et al. Neuroleptic-induced tardive dyskinesia and parkinsonism: changes during several years of continuing treatment. Psychopharmacol Bull 1986; 22:250-253.
137. Bergen JA, Eyland EA, Campbell JA, et al. The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry 1989; 154:523-528.
138. Munetz MR, Benjamin S. How to examine patients using the abnormal involuntary movement scale. Hosp Commun Psychiatry 1988; 39:1172-1177.
139. Davis JM, Schyve PM, Pavkovic I. Clinical and legal issues in neuroleptic use. Clin Neuropharmacol 1983; 6:117-128.
140. Kahne GJ. Rebound psychoses following the discontinuation of a high potency antipsychotic. Can J Psychiatry 1989; 34: 227-229.
141. Segraves RT. Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 1989; 46:275-284.
142. Chan J, Alldredge BK, Baskin LS. Perphenazine-induced priapism. DICP Ann Pharmacother 1990; 24:246-249.
143. Depression Guideline Panel: Depression in Primary Care: Volume 2. Treatment of Major Depression. Clinical Practice Guideline, Number 5. Rockville, MD. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93-0551. April, 1993.
144. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001; 57:161-178.
145. Brown WA, Johnson MF, Chen MG. Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res 1992; 41:203-214.
146. Fairchild CJ, Rush AJ, Vasavada N, et al. Which depressions respond to placebo? Psychiatry Res 1986; 18:217-226.
147. Khan A, Dager SR, Cohen S, et al. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology 1991; 4:125-130.
148. Downing RW, Rickels K. Predictors of response to amitriptyline and placebo in three outpatient treatment settings. J Nerv Mend Dis 1973; 156:109-129.
149. Parker G, Parker K, Austin MP, et al. Gender differences in response to differing antidepressant drug classes: two negative studies. Psychological Med 2003; 33:1473-1477.
150. Joyce PR, Mulder RT, Lury SE, et al. A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatr Scand 2003; 108:20-23.
151. Baca E. Garcia-Garcia M. Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 57-65.
152. Perry PJ. Pharmacotherapy for major depression with melancholic features: tricyclic versus selective serotonin reup-take inhibitor antidepressants. J Affective Disord 1996; 39: 1-6.
153. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9:139-143.
154. Rothschild AJ, Samson JA, Bessette MP. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression [see comment]. J Clin Psychiatry 1993; 54:338-342.
155. Rothschild AJ, Williamson DJ, Tohen MF, et al. A double blind randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004; 24:365-373.
156. Wolfersdorf M, Barg T, Konig F, et al. Paroxetine as antidepres-sant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychi-atry 1995; 28:56-60.
157. McGrath PJ, Stewart JW, Janal MN, et al. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 2000; 157:344-350.
158. Pande AC, Birkett M, Fechner-Bates S, et al. Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 1996; 40:1017-1020.
159. Reimherr FW, Wood DR, Byerley B, et al. Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984; 20: 70-72.
160. Stratta P, Bolino F, Cupillari M, et al. A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharmacol 1991; 6: 193-196.
161. Nemeroff CB, Evans DL, Gyulai L, et al. Double blind placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158:906-912.
162. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079-1088.
163. Ayd FJ. Patient compliance. Int Drug Ther Newsletter 1972; 7:33-40.
164. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press: 1995; 1081-1097.
165. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatric Clin N Am 1996; 19:371-386.
166. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19:427-434.
167. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243-1252.
168. American Psychiatric Association. Practice guideline for major depression disorder in adults. Am J Psychiatry 1993; 150(Suppl 4):1-26.
169. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988; 153(Suppl 3):69-76.
170. Montgomery SA, Dunbar GC. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993; 8:189-195.
171. Alexopoulos GS, Abrams RC. Depression in Alzheimer's disease. Psych Clin N Am 1991; 14:327-340.
172. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997; 154(May Suppl):1-39.
173. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. JAMA 1997; 278:1363-1371.
174. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003; 60:737-746.
175. Mendez MF, Cummings JL, Benson DF. Depression in epilepsy. Significance and phenomenology. Arch Neurology 1986; 43:766-770.
176. Robertson MM, Trimble MR. The treatment of depression in patients with epilepsy a double-blind trial. J Affective Disord 1985; 9:127-136.
177. Joffe RT, Lippert GP, Gray TA, et al. Personal and family history of affective illness in patients with multiple sclerosis. J Affect Disorder 1987; 12:63-65.
178. Benedetti F, Campori E, Colombo C, et al. Fluvoxamine treatment of major depression associated with multiple sclerosis. J Neuropsychiatry Clin Neurosci 2004; 16:364-366.
179. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990; 147:1493-1497.
180. Morris PLP, Robinson RG, Raphael B. Prevalence and course of depressive disorders in hospitalized stroke patients. Int J Psychiatry Med 1990; 20:349-364.
181. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of post-stoke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994; 25:1099-1104.
182. Lipsey JR, Robinson RG, Pearlson GD. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1984; 1:297-300.
183. Reding MJ, Orto LA, Winter SW, et al. Antidepressant therapy after stroke. A double blind trial. Arch Neurol 1986; 43: 763-765.
184. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000; 157:351-359.
185. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000; 31:1829-1832.
186. Jorge RE, Robinson RG, Arndt S, et al. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry 2003; 160:1823-1829.
187. Spalletta G, Guida G, Caltagirone C. Is left stroke a risk-factor for selective serotonin reuptake inhibitor antidepressant treatment resistance? J Neurology 2003; 250:449-455.
188. Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosom Med 1984; 46:199-212.
189. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treatment 2001; 70:1-10.
190. Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Prac 2003; 4:7.
191. Turkington RW. Depression masquerading as diabetic neuropathy. JAMA 1980; 243:1147-1150.
192. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000; 41:104-113.
193. Arnold LM, Hess EV, Hudson JI, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002; 112:191-197.
194. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2006; 119:5-15.
195. Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999; 156: 101-107.
196. Rabkin JG, Rabkin R, Harrison W, et al. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 1994; 151:516-523.
197. Schliefer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infaction. Arch Intern Med 1989; 149:1785-1789.
198. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosomatic Med 2004; 66:802-813.
199. Kavan MG, Elsasser GN, Hurd RH. Depression after acute myocardial infarction. Post Grad Med 1991; 89:83-89.
200. Strik JJ, Honig A, Lousberg R, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 2000; 62: 783-789.
201. Schlienger RG, Fischer LM, Jick H, et al. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Safety 2004; 27:1157-1165.
202. Wisner KL, Wheeler SB. Prevention of recurrent post-partum major depression. Hosp Community Psychiatry 1994; 45(12):1191-1196.
203. Appleby L, Warner R, Whitton A, et al. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ 1997; 314:932-936.
204. Goff D, Midha K, Sarid-Segal O, et al. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995; 117:417-423.
205. Buchanan RW, Kirkpatrick B, Bryant N, et al. Fluoxe-tine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996; 153:1625-1627.
206. Kramer MS, Vogel WH, DiJohnson C, et al. Antidepressants in depressed schizophrenic inpatients: a controlled trial. Arch Gen Psychiatry 1989; 46:922-928.
207. Prusoff BA, Williams DH, Weissman MM, et al. Treatment of secondary depression in schizophrenia: a double-blind, placebo-controlled trial of amitriptyline added to perphenazine. Arch Gen Psychiatry 1979; 36:569-575.
208. Spina E, DeDomenico P, Ruello, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994; 9:281-285.
209. Bradford D, Stroup S, Lieberman J. Pharmacological treatments for schizophrenia. In: A Guide To Treatments That Work, 2nd ed. Nathan PD, Gorman, JN, eds. Oxford University Press, 2002.
210. Wernicke JF, Dunlop SR, Dornseif BE, et al. Low dose fluox-etine therapy for depression. Psychopharmacol Bull 1988; 23:163-168.
211. DeWilde J, Spiers R, Mertens C, Bartholome F, et al. A double-blind comparative, multicentre study comparing paroxetine with fluoxetine in depressed
212. Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8:197-202.
213. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63:331-336.
214. Ray WA, Meredith S, Thapa PB, et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Therap 2004; 75:234-241.
215. Lipinski JF, Mallya G, Zimmerman P, et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50:339-342.
216. Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992; 53:119-122.
217. Patterson WM. Fluoxetine-induced sexual dysfunction (letter). J Clin Psychiatry 1993; 54:71.
218. Teicher MH, Gold C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment Am J Psychiatry 1990; 147:207-210.
219. Beasley CM, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br Med J 1991; 303:685-692.
220. Khan A, Khan S, Kolts R, et al. Suicide rates in clinical trials of SSRI, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160:790-792.
221. FDA: Labeling change request letter for antidepressants medications, 15 Oct. 2004. www.fda.gov/cder/drug/antidepressants/SSRIlabelChange.htm. Accessed November 15, 2004.
222. Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004; 18:1119-1132.
223. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996; 16:356-362.
224. Black K, Shea C, Dursun S, et al. Selective serotonin reup-take inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000; 25:255-261.
225. Doogan DP: Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharmacol 1991; 6 (Suppl 2): 47-56.
226. Dechant KL, Clissold SP. Paroxetine. Drugs 1991; 41:225-253.
227. Gardiner HM, Freeman CP, Jesinger DK, et al. Fluvoxamine: an open pilot study in moderately obese female patients suffering from atypical eating disorders and episodes of bingeing. Int J Obes Relat Metab Disord 1993; 17(5):301-305.
228. Woo MH, Smythe MA. Association of SIADH with selective serotonin reuptake inhibitors. Ann Pharmacother 1997; 31: 108-110.
229. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with SSRI and other antidepressants: a meta-analysis. Br J Psychiatry 2002; 180:396-404.
230. Stern WC, Harto-Truax N, Bauer N. Efficacy of bupropion in tricyclic resistant or intolerant patients. J Clin Psychiatry 1983; 44(sec 2):148-152.
231. Cole JO, Schatzberg AF, Sniffin C, et al. Trazodone in treatment-resistant depression an open study. J Clin Psychopharmacol 1981; 1(Suppl):49-54.
232. Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry 1990; 147:1203-1208.
233. Othmer E, Othmer S, Stern WC, et al. Long-term efficacy and safety of bupropion. J Clin Psychiatry 1983; 44(sec 2): 153-156.
234. Rouillon F, Serrurier D, Miller HD, et al. Prophylactic efficacy of maprotiline on unipolar depression relapse. J Clin Psychiatry 1991; 52:423-431.
235. Lydiard RB, Gelenberg AJ. Amoxapine: an antidepressant with some neuroleptic properties? A review of its chemistry, animal pharmacology and toxicology, human pharmacology, and clinical efficacy. Pharmacotherapy 1981; 1:163-178
236. Wickersham RM, Novak KK, Schweain SL, et al., eds. Drug Facts and Comparisons, 2004. St Louis, MO: Wolters Kluwer Health.
237. Wells BG, Gelenberg AJ. Chemistry, pharmacology, pharma-cokinetics, ADR, and efficacy of the antidepressant maprotiline hydrochloride. Pharmacotherapy 1981; 1:121-129.
238. Georgotas A, Forsell TL, Mann JJ, et al. Trazodone hydrochlo-ride: a wide spectrum antidepressant with a unique pharmacological profile. A review of its neurochemical effects, pharmacology, clinical efficacy, and toxicology. Pharmacotherapy 1982; 2:255-265.
239. Ellingrod VL, Perry PJ. Venlafaxine: A heterocyclic antidepres-sant. Am J Hosp Pharm 1995; 51:3033-3046.
240. Fatemi SH, Stary JM, Hatsukami DK, et al. A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia. Schizophr Res 2005; 76: 353-356.
241. Bielski RJ, Friedel DO. Prediction of tricyclic antidepres-sant response. A critical review. Arch Gen Psychiatry 1976; 33:1479-1489.
242. Morris JB, Beck AT. The efficacy of antidepressant drugs. A review of research (1958 to 1972). Arch Gen Psychiatry 1974; 30:667-674.
243. Klerman GL, Cole JO. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev 1965; 17:101-141.
244. Feinberg SS, Halbreich U. The association between the definition and reported prevalence of treatment-resistant depression. In: Halbreich U, Feinberg SS (eds): Psychosocial Aspects of Nonresponse to Antidepressant Drugs. Washington, DC, American Psychiatric Press, 1986; 5-34.
245. Avery D, Lubrano A. Depression treated with imipramine and ECT: the De Carolis study reconsidered. Am J Psychiatry 1979; 136:559-562.
246. Spiker DG, Dealy RS, Hanin I, et al. Treating delusional depres-sives with amitriptyline. J Clin Psychiatry 1986; 147:243-246.
247. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142:430-436.
248. Howarth BG, Grace MGA. Depression, drugs, and delusions. Arch Gen Psychiatry 1985; 42:1145-1147.
249. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: How long should it be maintained? Am J Psychiatry 1986; 143:18-23.
250. Prien RF, Klett CJ, Caffey EM. Lithium and imipramine in prevention of affective episodes: A comparison in recurrent affective illness. Arch Gen Psychiatry 1973; 29:420-425.
251. Coppen A, Ghose K, Montgomery S, et al. Continuation therapy with amitriptyline in depression. Br J Psychiatry 1978; 133:28-33.
252. Kocsis JH, Friedman RA, Markowitz JC, et al. Maintenance therapy for chronic depression: a controlled clinical trial of desipramine. Arch Gen Psychiatry 1996; 53:769-774.
253. Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989; 46:783-786.
254. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change. Arch Gen Psychiatry 1996; 53:785-792.
255. Perry PJ, Zeilmann C, Arndt SV. Tricyclic antidepressant plasma concentrations: An estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994; 14:230-240.
256. Devane CL, Jarecke CR. Cyclic antidepressants. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver, WA: Applied Therapeutics, 1992; 33:1-47.
257. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984; 230:94-102.
258. Glassman AH, Roose SP, Bigger JT. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 1993; 269:2673-2675.
259. Liebowitz MR, Quitkin FM, Stewart JW, et al. Phenelzine versus imipramine in atypical depression. Arch Gen Psychiatry 1984; 41:669-677.
260. McGrath PJ, Stewart JW, Harrison W, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993; 150:118-123
261. Anonymous: Emsam [selegiline] product information. 2006.
262. Sheehan DV, Claycomb JB, Kauretas N. Monoamine oxidase inhibitors: prescription and patient management. Int J Psychiatry Med 1980-1981; 10:99-121.
263. Stewart JW, Harrison W, Ouitkin F, et al. Phenelzine-induce pyridosine deficiency. J Clin Psychopharmacol 1984; 4: 225-226.
264. Grade C, Redford, B, Chrostowski J, et al. Methylphenidate in early poststroke recovery: a double blind placebo controlled study. Arch Physical Med Rehab 1998; 79: 1047-1050.
265. Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 1989; 50:241-249.
266. Hirschfeld RMA, Bowden CL, Gitlin MJ, et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159(Suppl):1-50.
267. Price LH, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med 1994; 331:591-598.
268. Goodwin FK, Murphy DL, Bunney WE Jr. Lithium carbonate treatment in depression and mania: a longitudinal double-blind study. Arch Gen Psychiatry 1969; 21:486-496.
269. Stokes PE, Shamoian CA, Stoll PM, et al. Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971; 1:1319-1325.
270. Schou M, Juel-Nielson, Stroomgren E, et al. The treatment of manic psychoses by administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17:250-260.
271. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of dival-proex vs lithium and placebo in the treatment of mania. JAMA 1994; 271:918-924.
272. Mirchandani IC, Young RC. Management of mania in the elderly: an update. Ann Clin Psychiatry 1993; 5:67-77.
273. Shopsin B, Gershon S, Thompson H, et al. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlor-promazine, and haloperidol. Arch Gen Psychiatry 1975; 32: 34-42.
274. Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999; 14:339-343.
275. Bowden CL, Grunze H, Mullen J, et al. A double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66:111-121.
276. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998; 21:176-180.
277. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159:1146-1154.
278. Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo controlled study. Bipolar Disord 2004; 6:213-223.
279. Lenox RH, Newhouse PA, Creelman WL, et al. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry 1992; 53:47-52.
280. Mendels J, Ramsey TA, Dyson WL, et al. Lithium as an antide-pressant. Arch Gen Psychiatry 1979; 36:845-846.
281. Perugi G, Micheli C, Akiskal HS, et al. Polarity of the first episode, clinical characteristics, and course of manic depressive illness: a systematic retrospective investigation of 320 bipolar I patients. Compr Psychiatry 2000; 41:13-18.
282. Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium? J Affect Disord 1986; 10:115-125.
283. Faedda GL, Tondo L, Baldessarini RJ, et al. Occurrence after rapid versus gradual discontinuation of lithium in bipolar disorders. Arch Gen Psychiatry 1993; 50:448-455.
284. Greil W, Schmidt ST. Lithium withdrawal reactions. In: Birch NJ (ed), Lithium: Inorganic Pharmacology and Psychiatric Use. Washington, DC, IRL Press 1998.
285. Solomon DA, Bauer MS. Continuation and maintenance phar-macotherapy for unipolar and bipolar mood disorders. Psychiatric Clin North Am 16:515-540.
286. Burrows GD. Long-term clinical management of depressive disorders. J Clin Psychiatry 1993; 55(Suppl 3):32-35.
287. Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999; 100:406-417.
288. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for one year with daily prospective ratings on the NIMH-Life Chart Method. J Clin Psychiatry 2003; 64:680-690.
289. Brodersen A, Licht RW, Vestergaard P, et al. Sixteen-year mortality in patients with affective disorder commended on lithium. Br J Psychiatry 2000; 176:429-433.
290. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290:1467-1473.
291. Lyskowski J, Nasrallah HA. Slow-release lithium: A review and a comparative study. J Clin Psychopharmacol 1981; 1: 406-408.
292. Kirkwood CK, Wilson SK, Hayes PE, et al. Single-dose bioavailability of two extended-release lithium carbonate products. Am J Hosp Pharm 1984; 51:486-489.
293. Vestergaard P, Hansen HE. Assessment of renal concentrating ability in lithium-treated patients. Comparison of long-term dehydration with administration of a vasopressin analogue. Acta Psychiatr Scand 1980; 62:152-156.
294. El-Mallakh RS. Acute lithium neurotoxicity. Psychiatric Dev 1986; 4:311-328.
295. DasGupta K, Jefferson JW. The use of lithium in the medically ill. Gen Hosp Psychiatry 1990; 12:83-97.
296. Gelenberg AJ, Jefferson JW. Lithium tremor. J Clin Psychiatry 1995; 56:283-287.
297. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-47.
298. Robinson JD, Lupkiewicz SM, Palenik L, et al. Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm 1983; 40:1016-1019.
299. Vestergaard P. Treatment and prevention of mania: a Scandinavian perspective. Neuropsychopharmacol 1992; 7: 249-259.
300. Hansen HE, Amdisen A. Lithium intoxication (report of 23 cases and review of 100 cases from the literature). Q J Med 1978; 47:123-144.
301. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146-150.
302. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals in human milk. Pediatrics 1994; 93: 137-150.
303. Klasco RK (Ed). DRUGDEX® System. Thomson MICROMEDEX, Greenwood Village, Colorado 2004.
304. Macritchie K, Geddes JR, Scott J, et al. Valproate for acute mood episodes in bipolar disorder (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley and Sons, Ltd.
305. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002; 159:1011-1017.
306. McElroy SL, Keck PE. Treatment guidelines for valproate in bipolar and schizoaffective disorders. Can J Psychiatry 1993; 38(Suppl 2):S62-S6.
307. Bowden CL, Janicak PG, Orsulak P, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153:765-770.
308. Wilder BJ. Pharmacokinetics of valproate and carbamazepine. J Clin Psychopharmacol 1992; 12:64S-68S.
309. Pugh CB, Garnett WR. Current issues in the treatment of epilepsy. Clin Pharm 1991; 10:335-358.
310. Dutta S, Zhang Y. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation. Biopharm Drug Dispos 2004; 25:345-352
311. Anonymous: Depakote [valproate] product information. 2003.
312. Jeavons PM. Sodium valproate and neural tube defects. Lancet 1982; 12:1282.
313. Briggs GG, Freeman RK, Yaffe SJ. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation, 4th ed. Baltimore: Williams and Wilkins, 1994.
314. Hale TW. Medications and Mother's Milk. 11th ed. Amarillo, TX: Pharmasoft Medical Publishing, 2004.
315. Post RM. Time course of clinical effects of carbamazepine: implications for mechanisms of action. J Clin Psychiatry 1988; 49(Suppl):35-46.
316. Lerer B, Moore N, Meyendorf E, et al. Carbamazepine versus lithium in mania. J Clin Psychiatry 1987; 48:89-93.
317. Small JC, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991; 48:915-921.
318. Grossi E, Sacchetti E, Vita A, et al. Carbamazepine vs chlor-promazine in mania: A double-blind trial. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam: Excerpta Medica, 1986; 177-187.
319. Okuma T, Inanga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study. Psychopharmacology 1979; 66:211-217.
320. Vasudev K, Goswani U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berlin) 2000; 150:15-23.
321. Emillen G, Maloteaux JM, Seghers A, et al. Lithium compared to valproic acid and carbamazepine in the treatment of mania: a statistical metal-analysis. Eur Neuropsychopharmacol 1996; 6:245-252.
322. Stromgren LS, Boller S. Carbamazepine in treatment and prophylaxis of manic-depressive disorder. Psychiatric Develop 1985; 4:349-367.
323. Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders-a randomized study. J Affect Disord 1997; 43: 151-161.
324. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58:470-478.
325. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10-11-epoxide. Clin Pharmacokinet 1986; 11:177-198.
326. Kudriakova TB, Sirota LA, Rozova GI, et al. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolite. Br J Clin Pharmacol 1992; 33:611-615.
327. Neppe VM, Tucker GJ, Wilensky AJ. Introduction: Fundamentals of carbamazepine use in neuropsychiatry. J Clin Psychiatry 1988; 49(Suppl 4):4-6
328. Anonymous: Tegretol [carbamazepine] product information. 2002.
329. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137:782-790.
330. Livingston S, Pauli L, Berman W. Carbamazepine in epilepsy. Nine year follow-up with special emphasis on untoward reactions. Dis Nerv Syst 1974; 35:103-107.
331. Denicoff KD, Meglathery SB, Post RM, et al. Efficacy of carbamazepine compared with other agents: A clinical practice survey. J Clin Psychiatry 1994; 55:70-76.
332. Isojarvi JIT, Pakarinen AJ, Myllyla VV. Thyroid function in epileptic patients treated with carbamazepine. Arch Neurol 1989; 46:1175-1178.
333. Sobotka JL, Alexander B, Cook BL. A review of carba-mazepine's hematologic reactions and monitoring recommendations. DICP Ann Pharmacother 1990; 24:1214-1219.
334. Soffer EE, Taylor RJ, Bertram PD, et al. Carbamazepine-induced liver injury. South Med J 1983; 76:681-683.
335. Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Eng J Med 1989; 320:1661-1666.
336. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994; 271:767-770.
337. Vajda F, O'Brien T, Hitchcock A, et al. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neuroscience 2003; 10:543-549.
338. Inoue H, Unno N. Excretion of verapamil in human milk. Br Med J 1984; 288:644-645.
339. Goldsmith DR, Wagstaff AJ, Ibbotson T, et al. Lamotrigine: a review of its use in bipolar disorder. Drugs 2003; 63: 2029-2050.
340. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60:79-88.
341. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in outpatients with bipolar I depression. J Clin Psychopharmacol 2000; 20:607-614.
342. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry 2000; 12:5-10.
343. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60:392-400.
344. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64:1013-1024.
345. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61: 841-850
346. Anonymous: Lamictal [lamotrigine] product information. 2003.
347. Emrich HM: Studies with oxcarbazepine (Trileptal) in acute mania. Int Clin Psychopharmacol 1990; 5(Suppl):83-88.
348. Reinstein MJ, Sonnenberg JG, Chasanov MA, et al. Oxcar-bazepine and divalproex sodium: a comparison of efficacy and side effects for mania (Abstract NR-354). Proceedings 154th Annual Meeting: New Orleans American Psychiatric Association, 5-10 May 2001.
349. Keck PE, McElroy SL, Nemeroff CB. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992; 4:395-405.
350. Dubovsky SL. Generalized anxiety disorder: new concepts and psychopharmacologic therapies. J Clin Psychiatry 1990; 51(Suppl):3-10.
351. Perry PJ, Garvey M, Noyes R. Benzodiazepine treatment of generalized anxiety disorder. In: Noyes R, Roth M, Burrows GD, eds. Handbook of anxiety. Treatment of anxiety. Vol 4. Amsterdam: Elsevier, 111-124, 1990.
352. Shapiro AK, Struening EL, Shapiro E, et al. Diazepam: how much better than placebo? J Psychiatr Res 1982; 17:51-73.
353. Zung WW. Effect of clorazepate on depressed mood in anxious patients. J Clin Psychiatry 1987; 48:13-14.
354. Kapczinski F, Lima MS, Souza JS, et al. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2003; CD003592.
355. Rickels K, Case G, Downing RW, et al. Long-term diazepam therapy and clinical outcome. JAMA 1983; 250:767-771.
356. Fricchione G. Clinical practice. Generalized anxiety disorder. N Engl J Med 2004; 351:675-682.
357. Gliatto MF. Generalized anxiety disorder. Am Fam Physician 2000; 62:1591-1600, 1602.
358. Andersch S, Rosenberg NK, Kullingsjo H, et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr Scand Suppl 1991; 365:18-27.
359. Ballenger JC, Burrows GD, DuPont RL Jr, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45:413-422.
360. Chouinard G, Annable L, Fontaine R, et al. Alprazolam in the treatment of generalized anxiety and panic disorders. A double-blind, placebo-controlled study. Psychopharmacology 1982; 77:229-233.
361. Dunner DL, Ishiki D, Avery DH, et al. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986; 47:458-460.
362. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev 1995; 15:819-844.
363. Noyes R, Anderson D, Clancy J. Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 1984; 41:287-292.
364. Rizley R, Kahn RJ, McNair DM, et al. A comparison of alpra-zolam and imipramine in the treatment of agoraphobia and panic disorder. Psychopharmacol Bull 1986; 22:167-172.
365. Sheehan DV. The management of panic disorder. J Clin Psychiatry 2002; 63(Suppl 14):17-21.
366. Sheehan DV, Coleman JH, Greenblatt DJ, et al. Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacol 1984; 4:66-75.
367. Sheehan DV, Raj AB, Harnett-Sheehan K, et al. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993; 88:1-11.
368. Sheehan DV. Is buspirone effective in the treatment of panic disorder? Presented at the New Clinical Drug Evaluation Unit annual meeting, Key Biscayne, Florida, May 28 1987.
369. Tesar GE, Rosenbaum JF, Pollack MH, et al. Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial. J Clin Psychiatry 1987; 48(Suppl):S16-9.
370. Uhlenhuth EH, Matuzas W, Glass RM, et al. Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989; 17:261-270.
371. Sheehan DV, Raj BA. Benzodiazepine treatment of panic disorder, in Handbook of Anxiety, Vol. 4. Edited by Noyes R, Roth M, Burrows G. Amsterdam, Elsevier, 1990; pp 169-206.
372. Munjack DJ, Crocker B, Cabe D, et al. Alprazolam, propra-nolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1989; 9: 22-27.
373. van Balkom AJ, Bakker A, Spinhoven P, et al. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 1997; 185: 510-516.
374. Pollack MH, Simon NM, Worthington JJ, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003; 17:276-282.
375. Goddard AW, Brouette T, Almai A, et al. Early coadministra-tion of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001; 58:681-686.
376. Pollack MH. Long-term management of panic disorder. J Clin Psychiatry 1990; 51(Suppl):11-13.
377. Bakker A, van Balkom AJ, Spinhoven P, et al. Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review. J Nerv Ment Dis 1998; 186:414-419.
378. Dommisse CS, Hayes PE. Current concepts in clinical therapeutics: anxiety disorders, part 2. Clin Pharm 1987; 6: 196-215.
379. Jefferson JW. Social phobia: a pharmacologic treatment overview. J Clin Psychiatry 1995; 56(Suppl 5):18-24.
380. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991; 48:938-945.
381. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13:423-428.
382. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004; 65:244-248.
383. Hollander E, Kaplan A, Stahl SM. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry 2003; 4:30-34.
384. Stein DJ, Hollander E, Mullen LS, et al. Comparison of clomipramine, alprazolam, and placebo in the treatment of obsessive-compulsive disorder. Human Psychopharmacology 1992; 7:389-395.
385. Braun P, Greenberg D, Dasberg H, et al. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990; 51:236-238.
386. Hollister LE. Pharmacotherapeutic considerations in anxiety disorders. J Clin Psychiatry 1986; 47(Suppl):33-36.
387. Chouinard G, Lefko-Singh K, Teboul E. Metabolism of anxi-olytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol 1999; 19:533-552.
388. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988; 49:293-301.
389. Bourin M, Lambert O. Pharmacotherapy of anxious disorders. Hum Psychopharmacol 2002; 17:383-400.
390. Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl) 1998; 139:402-406.
391. Mahe V, Balogh A. Long-term pharmacological treatment of generalized anxiety disorder. Int Clin Psychopharmacol 2000; 15:99-105.
392. Rouillon F. Long term therapy of generalized anxiety disorder. Eur Psychiatry 2004; 19:96-101.
393. Spier SA, Tesar GE, Rosenbaum JF, et al. Treatment of panic disorder and agoraphobia with clonazepam. J Clin Psychiatry 1986; 47:238-242.
394. Shebak S, Cameron A, Levander S. Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side effects. J Clin Psychiatry 1990; 51(Suppl)14-17.
395. Greenblatt DJ, Shader RI, Abernathy DR. Current status of benzodiazepines (first of two parts). N Engl J Med 1983; 309:354-358.
396. Greenblatt DJ. Benzodiazepines 1980: current update. Psycho-somatics 1980; 21(Suppl):9-14.
397. Greenblatt DJ. Benzodiazepines 1980: current update. Psycho-somatics 1980; 21(Suppl):26-31.
398. Greenblatt DJ, Shader RI. Prazepam and lorazepam, two new benzodiazepines. N Engl J Med 1978; 299:1342-1344.
399. Reidenberg MM, Levy M, Warner H, et al. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther 1978; 23: 371-374.
400. Thompson TL, Moran MG, Nies AS. Drug therapy: psychotropic drug use in the elderly (first of two parts). N Engl J Med 1983; 308:134-138.
401. Cole JO, Haskell DS, Orzack MH. Problems with benzodi-azepines: an assessment of the available evidence. McLean Hosp J 1981; 6:46-74.
402. Busto U, Sellers, EM, Naranjo CA, et al. Withdrawal reactions after long-term therapeutic use of benzodiazepines. N Engl J Med 1986; 315:854-859.
403. Perry PJ, Alexander B. Sedative/hypnotic dependence: patient stabilization, tolerance testing, and withdrawal. Drug Intell Clin Pharm 1986; 20:532-537.
404. Moller HJ. Effectiveness and safety of benzodiazepines. J Clin Psychopharmacol 1999; 19:2S-11S.
405. Tyrer P. Dependence as a limiting factor in the clinical use of minor tranquilizers. Pharmacol Ther 1988; 36:173-188.
406. Lucki I, Rickels K, Geller AM. Psychomotor performance following the long-term use of benzodiazepines. Psychophar-macol Bull 1985; 21:93-96.
407. Bauer RL. Traffic accidents and minor tranquilizers: a review. Public Health Rep 1984; 99:572-574.
408. Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Fam Physician 1998; 44:799-808.
409. Verster JC, Volkerts ER. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev 2004; 10:45-76.
410. Katcher BS. General care: anxiety and insomnia. In: Koda-Kimble MA, Katcher BS, Young LY, eds. Applied therapeutics for clinical pharmacists. 2nd ed. San Francisco: Applied Therapeutics, 1978; 71-85.
411. Gelenberg AJ. Amnesia and benzodiazepines. Bio Ther Psychiatry 1985; 8:27.
412. Salzman C. Behavioral side effects of benzodiazepines, in ADR of Psychotropic Drugs. Edited by Kane J, Lieberman J. New York, Guilford Press, 1992; pp 139-152.
413. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62:350-357.
414. Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160:749-756.
415. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997; 95:444-450.
416. Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolera-bility of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003; 64:250-258.
417. Allgulander C, Dahl AA, Austin C, et al. Efficacy of sertra-line in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004; 161:1642-1649.
418. Davidson JR, Bose A, Korotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004; 19:234-240.
419. Montgomery SA, Sheehan DV, Meoni P, et al. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res 2002; 36:209-217.
420. Katz IR, Reynolds CF 3rd, Alexopoulos GS, et al. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 2002; 50:18-25.
421. Otto MW, Tuby KS, Gould RA, et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001; 158:1989-1992.
422. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155:36-42.
423. Lecrubier Y, Bakker A, Dunbar G, et al. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95:145-152.
424. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167: 374-379.
425. Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 1998; 155:1570-1577.
426. Rapaport MH, Wolkow R, Rubin A, et al. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 2001; 104:289-298.
427. Leinonen E, Lepola U, Koponen H, et al. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 2000; 25:25-32.
428. Lepola UM, Wade AG, Leinonen EV, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998; 59:528-534.
429. Wade AG, Lepola U, Koponen HJ, et al. The effect of citalo-pram in panic disorder. Br J Psychiatry 1997; 170:549-553.
430. Pollack MH, Worthington JJ 3rd, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996; 32:667-670.
431. Baldwin D, Bobes J, Stein DJ, et al. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 1999; 175:120-126.
432. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998; 280:708-713.
433. Lader M, Stender K, Burger V, et al. Efficacy and tolerability of escitalopram in 12-and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004; 19:241-248.
434. Kasper S, Stein DJ, Loft H, et al. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005; 186:222-226.
435. Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999; 156: 756-760.
436. van Vliet IM, den Boer JA, Westenberg HG. Psychopharma-cological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994; 115:128-134.
437. Allgulander C, Mangano R, Zhang J, et al. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004; 19:387-396.
438. Sheehan DV, Davidson J, Manschreck T, et al. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 1983; 3: 28-31.
439. Den Boer JA, Westenberg GM. Effect of a serotonin and nora-drenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3:59-74.
440. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000; 283:1837-1844.
441. Davidson J, Pearlstein T, Londborg P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001; 158:1974-1981.
442. Zohar J, Amital D, Miodownik C, et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol 2002; 22:190-195.
443. Marshall RD, Beebe KL, Oldham M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001; 158: 1982-1988.
444. Tucker P, Zaninelli R, Yehuda R, et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62:860-868.
445. Schoenfeld FB, Marmar CR, Neylan TC. Current concepts in pharmacotherapy for posttraumatic stress disorder. Psychiatr Serv 2004; 55:519-531.
446. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55: 517-522.
447. Martenyi F, Brown EB, Zhang H, et al. Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry 2002; 181:315-320.
448. Martenyi F, Brown EB, Zhang H, et al. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry 2002; 63:199-206.
449. Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986; 47: 580-586.
450. Deltito JA, Argyle N, Klerman GL. Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. J Clin Psychiatry 1991; 52:121-127.
451. Gloger S, Brunhaus L, Gladic D, et al. Panic attacks and agoraphobia: low dose clomipramine treatment. J Clin Psychophar-macol 1989; 9:28-32.
452. Mavissakalian M, Perel J, Bowler K, et al. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry 1987; 144:785-787.
453. Munjack DJ, Rebal R, Shaner R, et al. Imipramine versus propranolol for the treatment of panic attacks: a pilot study. Compr Psychiatry 1985; 26:80-89.
454. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37:51-59.
455. Zitrin CM, Klein DF, Woerner MG, et al. Treatment of phobia. I. Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 1983; 40:125-138.
456. Allsopp LF, Cooper GL, Poole PH. Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Curr Med Res Opin 1984; 9:64-70.
457. Gringras M. An uncontrolled trial of clomipramine (Anafranil) in the treatment of phobic and obsessional states in general practice. J Int Med Res 1977; 5(Suppl 5):111-115.
458. Versiani M, Mundim FD, Nardi AE, et al. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988; 8:279-283.
459. Davidson J, Kudler H, Smith R, et al. Treatment of posttrau-matic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990; 47:259-266.
460. Frank JB, Kosten TR, Giller EL Jr, et al. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry 1988; 145:1289-1291.
461. Reist C, Kauffmann CD, Haier RJ, et al. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry 1989; 146:513-516.
462. Noyes R Jr, Garvey MJ, Cook BL, et al. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989; 50:163-169.
463. Ballenger JC. Pharmacotherapy of the panic disorders. J Clin Psychiatry 1986; 6(Suppl):27-32.
464. Jann MW, Kurtz NM. Treatment of panic and phobic disorders. Clin Pharm 1987; 6:947-962.
465. Solyom L, Heseltine GF, McClure DJ, et al. Behaviour therapy versus drug therapy in the treatment of phobic neurosis. Can Psychiatr Assoc J 1973; 18:25-32.
466. Solyom L, Heseltine GR, McClure DJ, et al. A comparative study of aversion relief and systematic desensitization in the treatment of phobias. Br J Psychiatry 1971; 119:299-303.
467. Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia 1973; 32:237-254.
468. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992; 49:290-300.
469. Versiani M, Nardi AE, Mundim FD, et al. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161:353-360.
470. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998; 55:1133-1141.
471. Shestatzky M, Greenberg D, Lerer B. A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res 1988; 24:149-155.
472. Pecknold JC, Swinson RP, Kuch K, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Arch Gen Psychiatry 1988; 45:429-436.
473. Coryell W, Noyes R, Clancy J. Panic disorder and primary unipolar depression: a comparison of background and outcome. J Affect Disord 1983; 5:311-317.
474. Goldberg HL. Buspirone hydrochloride: a unique new anxi-olytic agent. Pharmacotherapy 1984; 4:314-324.
475. Dommisse CS, DeVane CL. Buspirone: a new type of anxi-olytic. Drug Intell Clin Pharm 1985; 19:624-628.
476. Pohl R, Balon R, Yeragani VK, et al. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 1989; 2(Suppl):S60-67.
477. Newton RE, Casten GP, Alms DR, et al. The side effect profile of buspirone in comparison to active controls and placebo. J Clin Psychiatry 1982; 43:100-102.
478. Seppala T, Aranko K, Matilla MJ, et al. Effects of alcohol on buspirone and lorazepam actions. Clin Pharmacol Ther 1982; 32:201-207.
479. Moskorvitz H, Smiley A. Effects of chronically administered buspirone and diazepam on driving-related skills performance. J Clin Psychiatry 1982; 43:45-56.
480. Matilla MJ, Aranko K, Seppala T. Acute effects of buspirone and alcohol on psychomotor skills. J Clin Psychiatry 1982; 43:56-60.
481. Lader M. Beta-adrenoceptor antagonists in neuropsychiatry: an update. J Clin Psychiatry 1988; 49:213-223.
482. Shuckit MA. Current therapeutic options in the management of typical anxiety. J Clin Psychiatry 1981; 142(sec 2):15-26.
483. Goodman WK, McDougle CJ, Barr LC, et al. Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 1993; 54(Suppl):16-26.
484. Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 1995; 166:424-443.
485. Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv 2003; 54:1111-1118.
486. Wheadon D, Bushnell W, Steiner M. A fixed dose comparison of 20, 40, and 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder. Paper presented to the Annual Meeting of the American College of Neuropharma-cology; 1993.
487. Koran LM, Hackett E, Rubin A, et al. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 2002; 159:88-95.
488. Denys D, van der Wee N, van Megen HJ, et al. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003; 23: 568-575.
489. Todorov C, Freeston MH, Borgeat F. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible? Can J Psychiatry 2000; 45:257-262.
490. McDougle CJ, Goodman WK, Leckman JF, et al. The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis. Psychiatr Clin North Am 1993; 16:749-766.
491. Thoren P, Asberg M, Cronholm B, et al. Clomipramine treatment of obsessive-compulsive disorder, I: a controlled clinical trial. Arch Gen Psychiatry 1980; 37:1281-1285.
492. Insel TR. New Findings in Obsessive-Compulsive Disorder. American Psychiatry Press, Washington D.C. 1984.
493. Ananth J. Clomipramine an antiobsessive drug. Can J Psychiatry 1986; 31:253-258.
494. Zohar J, Insel TR. Drug treatment of obsessive-compulsive disorder. J Affective Disord 1987; 13:193-202.
495. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobio-logic approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987; 22:667-687.
496. Leonard H, Swedo S, Rapoport JL, et al. Treatment of childhood obsessive-compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacol Bull 1988; 24:93-95.
497. Murphy DL, Zohar J, Benkelfat C, et al. Obsessive-compulsive disorder as a serotonin subsystem-related behavioral disorder. Br J Psychiatry 1989; 155(Suppl 8):15-24.
498. DeVeaugh-Geiss J, Landau P, Katz R. Treatment of obsessive-compulsive disorder with clomipramine. Psychiatric Annals 1989; 19:97-101.
499. Monteiro WO, Noshirvani HF, Marks IM, et al. Anor-gasmia from clomipramine in obsessive-compulsive disorder: a controlled trial. Br J Psychiatry 1987; 151:107-112.
500. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med 1999; 341:1670-1679.
501. Rogers SL, Farlow MR, Doody RS, et al. Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50:136-145.
502. Burns A, Russell E, Page S. New drugs for Alzheimer's disease. Br J Psychiatry 1999; 174:476-479.
503. Mega MS, Masterman DM, O'Connor SM, et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer's Disease. Arch Neurol 1999; 56:1388-1393.
504. Doody R, Geldmacher D, Gordon B, et al. Open-label, multi-center, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58:427-433.
505. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003; 51: 737-744.
506. Feldman H, Gauthier S, Hecker J. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo controlled trial. Int J Geriatr Psychiatry 2005; 20:559-569.
507. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized control trial. BMJ 1999; 318:633-638.
508. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. J Geriatr Psychophar-macol 1998; 1:55-65.
509. Wilkinson D, Murray J. Galantamine. A randomized, double-blind, dose comparison in patients with Alzheimer's disease. Intl J Geriatr Psychiatry 2001; 16:852-857.
510. Rive B, Vercelletto M, Damier FD, et al. Memantine enhances autonomy in moderate to severe Alzheimer's disease. Intl J Geriatr Psychiatry 2004; 19:458-464.
511. Tariot P, Farlow M, Grossberg G. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 2004; 294:317-324.
512. Roane DM, Feinberg TE, Meckler L, et al. Treatment of dementia-associated agitation with gabapentin. J Neuropsychi-atry Clin Neurosci 2000; 12:40-43.
513. Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994; 42:1160-1166.
514. Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbances in dementia. J Geriatr Psychitary Neurol 1993; 6:203-209.
515. Lott DA, McElroy SL, Keys MA. Valproate in the treatment of behavioral agitation in elderly patients with dementia. J Neuropsychiatry Clin Neurol 1995; 7:314-319.
516. Grossman F. A review of anticonvulsants in treating agitated demented elderly patients. Pharmacotherapy 1998;18:600-606.
517. Schenck CH, Mahowald MW, Sack RL. Assessment and management of insomnia. JAMA 2003; 289:2475-2479.
518. Krystal AD. The changing perspective on chronic insomnia management. J Clin Psychiatry 2004; 65(Suppl 8):20-25.
519. Holbrook AM, Crowther R, Lotter A, et al. The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach. Can Med Assoc 2000; 162:216-220
520. Anonymous: Lunesta [eszopiclone] product information. 2005
521. Anonymous: Rozerem [ramelteon] product information. 2005.
522. Perry PJ, Alexander B, Garvey MJ. Clinical psychophar-macology and other somatic therapies. In: Winokur G and Clayton P eds. The Medical Basis of Psychiatry, 2nd ed. Philadelphia: Saunders, 1994:545-588.